ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior...

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2- positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory...

ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: Have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer. Your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery).

In order to prevent medicinal product errors, it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Enhertu (trastuzumab deruxtecan) and not trastuzumab or trastuzumab emtansine. Enhertu should not be substituted with trastuzumab or trastuzumab emtansine.

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:

2021年4月15日 · In order to prevent medicinal product errors, it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Enhertu (trastuzumab deruxtecan) and not trastuzumab or trastuzumab emtansine. Enhertu should only be used in patients with documented HER2-positive tumour status (see 14 CLINICAL TRIALS).

2024年4月10日 · ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a …

6 天之前 · On January 27, 2025, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH ...

The recommended dosage of ENHERTU is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21 -day cycle) until disease progression or unacceptable toxicity. Recommended Dosage for...

2025年2月2日 · Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 gene mutations. Includes Enhertu side effects, uses, package insert and more.